Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Dec 12, 2021 1:59pm
110 Views
Post# 34223171

RE:RE:RE:RE:RE:RE:Listened to the Stifel-GMP call again ...

RE:RE:RE:RE:RE:RE:Listened to the Stifel-GMP call again ...Hahaha - finally saying 7 years ... first real number they could muster up and I''m thinking that in itself is a mistake.             

: )

I'm pretty sure the financials show they are not losing money ... as we've discussed ad nauseam - so I won't list the annual incomes again.  I will just say GUD has accumulated close to $300M in income over the years.

In my opinion - the fact that investors haven't jumped on board yet is a God sent.  I am totally at peace with that fact.  I consider it an accumulation advantage.

-------------------------







Snowballgrowth wrote:
Chianchin wrote: ...and they keep loosing a ton of money and market cap for 7 Years. I suppose loosing fortune's Mr mugsy knows better than Bay street institutional investors who are busy dumping shares and the only bidder left is GUD with PP money 


Why do you say this ? National bank, Royal Bank and all other analysts wrote positive reports after the last quarter results. 

NB sees $ 295 M revenues and $ 60 M adjusted EBITDA for 2022. What are your forecast ?



<< Previous
Bullboard Posts
Next >>